MidWest Drug Development Conference, hosted by UNeMed, the technology transfer and commercialization office for the University of Nebraska Medical Center and the University of Nebraska at Omaha.
www.mwdrugdevelopment.com
OMAHA, Nebraska (July 30, 2021)—The final slate of participants and sponsorships for the 2021 MidWest Drug Development Conference are nearly filled as several major institutions have lined up to participate in the event.
Sponsored in part by PhRMA, a massive international trade association that advocates and supports pharmaceutical companies, the conference will feature 18 major Midwest institutions.
Among the participating research institutions are biomedical heavyweights such as Mayo Clinic, Wisconsin Alumni Research Foundation, Ohio State University, Cincinnati Children’s Hospital and University of Minnesota.
The impressive list of participating research institutions continues, including Colorado Anschutz Medical Campus, Colorado-Boulder, Colorado State, Indiana, Iowa, Kansas, Kansas State, Kentucky, Missouri, University of Nebraska Medical Center, Oklahoma, Purdue and South Dakota.
Joining PhRMA as primary sponsors of the event are SHARPHub, Olon Ricera Bioscience, Marshall Gerstein, UNeMed and the University of Nebraska Medical Center.
Each participating institution will highlight new therapeutics under development. The conference will span two days, beginning on Oct. 4, and will feature about 40 novel technologies in 10-minute presentations. Specific details about those presentations can be viewed here: https://www.mwdrugdevelopment.com/technologies/.
The 18 institutions account for a massive amount of research and innovation in the region, according to the latest data from the Association of University Technology Managers, or AUTM. In 2019, the participating universities spent a combined $9.63 billion in research, which led to 3,699 new inventions. They secured 1,049 U.S. patents, produced 211 new products and formed 123 startup companies. They also signed 832 licensing agreements, 39 of which were worth more than $1 million each.
A key feature of the conference is the ability for participants to set up one-on-one partnering meetings between researchers, tech transfer professionals, industry representatives, investors and other interested parties. Previous attendees have included representatives from such companies as AbbVie Ventures, Atlas Ventures, GlaxoSmithKline, Merck and Pfizer, to name a few.
The conference begins on Monday, Oct. 4, and concludes the following day, Tuesday, Oct. 5. It will be at the Capital District Marriott in downtown Omaha.
Cost is $500 per ticket, but organizers will waive a limited number of registration fees for those who represent pharmaceutical and biotech companies and investment groups. Contact conference organizers to learn how to receive a waiver code.
Register here: https://www.mwdrugdevelopment.com/tickets/.
